Skip to main
COLL
COLL logo

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. has demonstrated a robust growth trajectory, as evidenced by a 2% quarter-over-quarter increase in Jornay PM prescriptions during both 2Q25 and 3Q25, along with a significant 24% year-over-year growth in total prescriptions from 1Q24 to 1Q25. The company has revised its 2025 guidance, reflecting a positive outlook with projected top-line expectations raised to $745 million to $760 million, while also forecasting an adjusted EBITDA growth to between $440 million and $455 million. Additionally, Jornay PM sales for 2Q25 reached $32.6 million, showing a 14% quarter-over-quarter increase and exceeding the growth rates in its prescriptions, further supporting a favorable financial outlook for the company.

Bears say

Collegium Pharmaceutical has experienced mixed performance in its pain portfolio, with prescriptions for Xtampza ER and Nucynta showing declines of 1% and 2%, respectively, which may reflect challenges in market acceptance. Additionally, concerns about the company's reliance on third-party suppliers for product quality and regulatory compliance could hinder commercialization efforts and profit margins. With impending potential losses of exclusivity for key products like Nucynta and Belbuca in 2027, the company faces significant risks that could adversely impact future cash flows and overall financial health.

Collegium Pharmaceutical (COLL) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 3 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.